KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 0.78.

  • Vir Biotechnology's Equity Ratio fell 569.43% to 0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.78, marking a year-over-year decrease of 569.43%. This contributed to the annual value of 0.82 for FY2024, which is 75.46% down from last year.
  • Latest data reveals that Vir Biotechnology reported Equity Ratio of 0.78 as of Q3 2025, which was down 569.43% from 0.79 recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Equity Ratio registered a high of 0.86 during Q1 2024, and its lowest value of 0.57 during Q1 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.79 (2025), whereas its average is 0.77.
  • In the last 5 years, Vir Biotechnology's Equity Ratio plummeted by 2809.03% in 2021 and then surged by 2090.8% in 2022.
  • Over the past 5 years, Vir Biotechnology's Equity Ratio (Quarter) stood at 0.73 in 2021, then rose by 1.21% to 0.74 in 2022, then grew by 11.74% to 0.83 in 2023, then fell by 0.75% to 0.82 in 2024, then decreased by 5.05% to 0.78 in 2025.
  • Its last three reported values are 0.78 in Q3 2025, 0.79 for Q2 2025, and 0.8 during Q1 2025.